Matthew D. Cascino

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Richard Furie, Gustavo Aroca, Matthew D. Cascino et al. · Annals of the Rheumatic Diseases · 2022 · 438 citations · Full text

Life Sciences, Clinical Sciences, Immunology +16

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis

Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg et al. · Clinical Journal of the American Society of Nephrology · 2018 · 183 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Mathematical modeling of cancer radiovirotherapy

David Dingli, Matthew D. Cascino, Krešimir Josić́ et al. · Mathematical Biosciences · 2005 · 141 citations

Medicine, Cancer Biology, Oncology +11

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant

Robert R. Redfield, Stanley C. Jordan, Stéphan Busque et al. · American Journal of Transplantation · 2019 · 79 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +17

A Population‐Based Study of Infection‐Related Hospital Mortality in Patients With Dermatomyositis/Polymyositis

Sara G. Murray, Gabriela Schmajuk, Laura Trupin et al. · Arthritis Care & Research · 2014 · 75 citations

Medicine, Infectious Diseases, Internal Medicine +14